Osteoarthritis News and Research

Latest Osteoarthritis News and Research

Positive results from Winston Laboratories' Civamide Patch trial

Winston Laboratories, Inc., a wholly-owned subsidiary of Winston Pharmaceuticals, Inc. today announced positive top-line results from Study WL1001-04-03, a Phase II clinical trial evaluating the safety and efficacy of the company's patch formulation of Civamide, a novel TRPV-1 receptor modulator in the treatment of post-herpetic neuralgia (PHN).

16 Nov 2009

Galapagos third quarter 2009 financial results in line with management expectations

Galapagos NV announces today that third quarter 2009 operational and financial results were in line with management expectations. These results encourage the Company to retain full year guidance of EUR 100 million revenues, a growth of 30% compared to 2008. Galapagos' service division BioFocus will significantly increase its cash contribution to the Group result for the full year 2009.

13 Nov 2009

Abbott signs agreement to acquire global rights to PanGenetics BV's PG110

Abbott announced today a definitive agreement to acquire the global rights to PanGenetics BV's PG110 fully humanized antibody to Nerve Growth Factor (NGF), expanding the company's pain care portfolio and leveraging its expertise in biologics. PG110 is a novel biologic in Phase I clinical trial development that targets NGF for the treatment of chronic pain.

13 Nov 2009

Abbott to acquire the global rights to PanGenetics' new therapeutic for treatment of chronic pain

PanGenetics, an antibody development company which is developing PG110, a humanized antibody to Nerve Growth Factor (NGF), today announced it has entered into an agreement with Abbott under which Abbott will acquire the global rights to this novel biologic. PG110 is currently in a Phase 1 clinical trial in patients with osteoarthritis and represents a promising new therapeutic for the treatment of chronic pain.

13 Nov 2009

Results from first-in-man study of NO-donating HMG-CoA Reductase Inhibitor released

NicOx S.A. today announced that a phase 1b, first-in-man study for NCX 6560, versus placebo and Lipitor® (atorvastatin), has met its primary and secondary objectives. The top-line results demonstrated very good safety and tolerability for all the tested doses of NCX 6560, as well as the expected cholesterol lowering profile.

13 Nov 2009

Endo Pharmaceuticals reaches patent litigation settlement with LecTec

Endo Pharmaceuticals announced today that it has reached a settlement with LecTec Corporation on outstanding patent litigation related to LecTec's U.S. Patent Nos. 5,536,263 and 5,741,510.

11 Nov 2009

GeneNews discloses financial results for third-quarter 2009

GeneNews Limited, a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today reported operational and financial results for the third quarter-ended September 30, 2009.

11 Nov 2009

BioClinica to host a seminar on medical imaging for rheumatoid arthritis in clinical trials

BioClinica™, Inc., (NASDAQ: BIOC), a global provider of clinical trial services, today announced it will be hosting a seminar on November 18, 2009 highlighting new research, trends and updates from industry experts in rheumatoid arthritis. This event, which will be held in Lafayette, PA, is part of the continuing series of symposia hosted by the company for pharmaceutical and medical imaging executives over the past four years that addresses the challenges and approaches in conducting clinical trials.

From Clario 11 Nov 2009

Third quarter 2009 financial results announced by IntelGenx Technologies

IntelGenx Technologies Corp. (TSX VENTURE:IGX) (OTCBB:IGXT) ("IntelGenx") today announced its results, reported in US dollars, for the three and nine months ended September 30, 2009.

10 Nov 2009

Emisphere Technologies' key product developments and financial results for the third quarter of 2009

Emisphere Technologies, Inc. today announced financial and operational results for the third quarter and nine months ended September 30, 2009.

9 Nov 2009

Public health experts urge Congress not to overlook the needs of Americans with "morbid obesity"

As the House of Representatives and the Senate debate companion bills to make health care more affordable and accessible, a coalition of obesity and public health experts today urged Congress not to overlook the needs of the more than 15 million Americans who suffer from severe obesity and are at the greatest risk for chronic disease and death.

9 Nov 2009

FDA approves the New Drug Application for Pennsaid Topical Solution

Covidien, a leading global provider of healthcare products, and Nuvo Research Inc., a Canadian drug development company, today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for Pennsaid(R) Topical Solution (diclofenac sodium topical solution) 1.5% w/w.

5 Nov 2009

Pennsaid Topical Solution approved by FDA

Covidien, a leading global provider of healthcare products, and Nuvo Research Inc. (TSX:NRI), a Canadian drug development company, today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for Pennsaid® Topical Solution (diclofenac sodium topical solution) 1.5% w/w.

5 Nov 2009

Financial results for third-quarter 2009 announced by Combinatorx

CombinatoRx, Incorporated today reported financial results for the third quarter ended September 30, 2009.

3 Nov 2009

Adults who experienced physical abuse as children at a higher risk of osteoarthritis, says study

Adults who had experienced physical abuse as children have 56 per cent higher odds of osteoarthritis compared to those who have not been abused, according to a new study by University of Toronto researchers.

3 Nov 2009

Amylin and Takeda to develop and commercialize pharmaceutical products for obesity

Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Takeda Pharmaceutical Company Limited (TSE: 4502) announced today that they have entered into a worldwide exclusive license, development and commercialization agreement to co-develop and commercialize pharmaceutical products for the treatment of obesity and related indications.

2 Nov 2009

Third-quarter fiscal 2009 results announced by Adolor

Adolor Corporation today reported a net loss of approximately $11.1 million, or ($0.24) per basic and diluted share, for the three months ended September 30, 2009 compared to a net loss of $13.3 million, or ($0.29) per basic and diluted share, for the three months ended September 30, 2008.

29 Oct 2009

Third-quarter fiscal 2009 results announced by Endo Pharmaceuticals

Endo Pharmaceuticals today reported financial results for the third quarter of 2009.

29 Oct 2009

AMT inks agreement with Progenika Biopharma for development of LPLchip

Amsterdam Molecular Therapeutics (AMT) and Progenika Biopharma announced today that the companies have entered into a development and commercialization agreement for LPLchip(TM), a diagnostic tool to rapidly diagnose patients with complete and partial lipoprotein lipase deficiency (LPLD). AMT has developed Glybera(R) as a gene therapy for patients with this disease.

29 Oct 2009

Third-quarter fiscal 2009 results announced by POZEN

POZEN Inc., today announced results for the third quarter ended September 30, 2009.

28 Oct 2009

Osteoarthritis News and Research

Latest Osteoarthritis News and Research

Positive results from Winston Laboratories' Civamide Patch trial

Galapagos third quarter 2009 financial results in line with management expectations

Abbott signs agreement to acquire global rights to PanGenetics BV's PG110

Abbott to acquire the global rights to PanGenetics' new therapeutic for treatment of chronic pain

Results from first-in-man study of NO-donating HMG-CoA Reductase Inhibitor released

Endo Pharmaceuticals reaches patent litigation settlement with LecTec

GeneNews discloses financial results for third-quarter 2009

BioClinica to host a seminar on medical imaging for rheumatoid arthritis in clinical trials

Third quarter 2009 financial results announced by IntelGenx Technologies

Emisphere Technologies' key product developments and financial results for the third quarter of 2009

Public health experts urge Congress not to overlook the needs of Americans with "morbid obesity"

FDA approves the New Drug Application for Pennsaid Topical Solution

Pennsaid Topical Solution approved by FDA

Financial results for third-quarter 2009 announced by Combinatorx

Adults who experienced physical abuse as children at a higher risk of osteoarthritis, says study

Amylin and Takeda to develop and commercialize pharmaceutical products for obesity

Third-quarter fiscal 2009 results announced by Adolor

Third-quarter fiscal 2009 results announced by Endo Pharmaceuticals

AMT inks agreement with Progenika Biopharma for development of LPLchip

Third-quarter fiscal 2009 results announced by POZEN

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Osteoarthritis News and Research

Latest Osteoarthritis News and Research

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in